The Food and Drug Administration yesterday updated its Risk Evaluation and Mitigation Strategy for extended-release and long-acting opioid analgesics, and extended the same requirements to immediate-release opioid analgesic products. The REMS applies to 347 opioid analgesics intended for outpatient use. Among other changes, the updates modify the prescriber education blueprint to include more information on pain management and require manufacturers to make training available to other, non-physician prescribers, such as nurses and pharmacists involved in pain management. FDA announced the planned updates last year. In other news, the Centers for Disease Control and Prevention recently released a resource to help health care providers implement its guidelines for prescribing opioids for chronic pain.

Related News Articles

Headline
The House Committee on Oversight and Reform today held the third in a series of hearings examining solutions to the opioid epidemic, which focused on the…
Headline
The Food and Drug Administration today published a notice seeking comment through July 30 on a potential change to the Opioid Analgesic Risk Evaluation and…
Headline
The Health Resources and Services Administration yesterday awarded 120 organizations, including hospitals, $200,000 each to develop community partnerships and…
Headline
Laws that allow pharmacists to dispense the opioid antidote naloxone without a physician’s prescription are associated with a sharp reduction in fatal opioid-…
Headline
The White House Office of National Drug Control Policy seeks by 2022 to reduce drug overdose deaths and youth illicit drug use by 15 percent and opioid…
Perspective
Investing in our country’s health infrastructure is the right move to make.